Patterns of Cerebellar Atrophy and Resting State Functional Connectivity Changes in Relapsing-Remitting MS Patients Starting Fingolimod and Natalizumab: A 2-Year Study (1314)

Paolo Preziosa; Paola Valsasina; Loredana Storelli; Elisabetta Pagani; Lucia Moiola; Mariaemma Rodegher; Maria A. Rocca; Massimo Filippi

doi:10.1212/wnl.94.15_supplement.1314

Shared by

Massimo Filippi

Patterns of Cerebellar Atrophy and Resting State Functional Connectivity Changes in Relapsing-Remitting MS Patients Starting Fingolimod and Natalizumab: A 2-Year Study (1314)

Article 2020 en

Authors

PP
Paolo Preziosa
PV
Paola Valsasina
LS
Loredana Storelli

Abstract

1 min read

To compare the effects of fingolimod and natalizumab on cerebellar atrophy and resting state (RS) functional connectivity (FC) in relapsing-remitting multiple sclerosis (RRMS) after two years of treatment.

Discussion(0)

No comments yet. Be the first to comment.

Patterns of Cerebellar Atrophy and Resting State Functional Connectivity Changes in Relapsing-Remitting MS Patients Starting Fingolimod and Natalizumab: A 2-Year Study (1314)

Abstract

Discussion(0)

Related publications

Modulation of Large-Scale Functional Networks Occurs in MS Patients Starting Fingolimod or Natalizumab: A 2-Year Resting State Functional Connectivity Study (S31.003)

Patterns of Regional Gray Matter and White Matter Atrophy in Patients Starting Fingolimod or Natalizumab: A 2-Year Tensor-Based Morphometry Study (P1.377)

Effects of Fingolimod and Natalizumab on Brain T1/T2-Weighted and Magnetization Transfer Ratios: A 2-Year Study (1486)

The Effects of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Relapsing Remitting Multiple Sclerosis: A One-Year Comparative Study (P6.152)

The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073)

Related publications

Article2019
Modulation of Large-Scale Functional Networks Occurs in MS Patients Starting Fingolimod or Natalizumab: A 2-Year Resting State Functional Connectivity Study (S31.003)
Article2019

Article2018
Patterns of Regional Gray Matter and White Matter Atrophy in Patients Starting Fingolimod or Natalizumab: A 2-Year Tensor-Based Morphometry Study (P1.377)
Article2018

Article2020
Effects of Fingolimod and Natalizumab on Brain T1/T2-Weighted and Magnetization Transfer Ratios: A 2-Year Study (1486)
Article2020

Article2015
The Effects of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Relapsing Remitting Multiple Sclerosis: A One-Year Comparative Study (P6.152)
Article2015

Article2017
The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073)
Article2017